Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Background and aim Previous studies showed that renal dysfunction was associated with both a reduction in serum high-density lipoprotein (HDL) cholesterol concentration and increased circulating monocyte count. We aimed to investigate the effect of circulating monocyte to serum HDL cholesterol ratio (M/H ratio) on fatal and composite cardiovascular events, in an observational cohort study of chronic kidney disease (CKD) patients.Materials and methods A total of 340 subjects with stage 1-5 CKD were followed for a mean follow-up period of 33 (range 2-44) months and assessed for fatal and nonfatal CV events. M/H ratio was calculated for all patients. All-cause mortality and CVE were also analyzed in relation to M/H ratio.Results Monocyte/HDL cholesterol ratio was negatively correlated with estimated glomerular filtration rate (eGFR) (r = -0.43, P < 0.001). Notably, both fatal and combined fatal and nonfatal cardiovascular events were more common in patients having a M/H ratio in the third tertile was associated with a hazard ratio of 2.24 and 4.91, respectively, for fatal and composite cardiovascular events compared to being in the first tertile.Conclusion Monocyte/HDL cholesterol ratio was increased with decreasing eGFR in predialytic CKD patients. Most importantly, we report for the first time that an increased M/H ratio was cross-sectionally associated with a worse cardiovascular profile and arose as independent predictors of major cardiovascular events during follow-up.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and through multivariate analysis, this ratio was found to be an independent predictor of low FFR values [26].”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [26]
In the citing paper
“It was demonstrated that patients with hemodynamically significant stenosis (FFR ≤ 0.80) had higher MHR values, and through multivariate analysis, this ratio was found to be an independent predictor of low FFR values [26].”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [26]
Citations
Cites
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease
Massry, S. G., Coburn, J. W., Chertow, G. M., Hruska, K. A., Langman, C. B., Malluche, H. H., Martin, K. J., McCann, L. M., McCarthy, J. T., Moe, S. M., et al. (2003) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 2,527
(2007) · The Lancet · doi:10.1016/s0140-6736(07)61778-4 · Cited by 2,331 · cited 2×
“In the presence of excessive metabolic and oxidative stress (such as in uremia), HDL might lose its protective effect and may behave as a pro-inflammatory molecule [12].”
BackgroundK/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.
(2003) · PubMed · Cited by 1,394
Monocytes in atherosclerosis: subsets and functions
Woollard, K. J., & Geissmann, F. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2009.228 · Cited by 890 · cited 1×
“Plaque macrophages account for the majority of leukocytes in plaques and are believed to be different from monocytes recruited from circulating blood [1].”
BackgroundAnsell, B. J., Navab, M., Hama, S., Kamranpour, N., Fonarow, G., Hough, G., Rahmani, S., Mottahedeh, R., Dave, R., Reddy, S. T., et al. (2003) · Circulation · doi:10.1161/01.cir.0000103624.14436.4b · Cited by 590 · cited 1×
“Inflammatory/anti-inflammatory properties of HDL also distinguish better patients that are favorably affected by simvastatin treatment [14].”
BackgroundAdhesion mechanisms regulating the migration of monocytes
Imhof, B. A., & Aurrand-Lions, M. (2004) · Nature Reviews Immunology · doi:10.1038/nri1375 · Cited by 584 · cited 1×
“Recruited monocytes facing fatty deposits undergo activation and accumulate as foam cells [2, 3].”
BackgroundHigh-Density Lipoprotein Reduces the Human Monocyte Inflammatory Response
Murphy, A. J., Woollard, K. J., Hoang, A., Mukhamedova, N., Stirzaker, R. A., McCormick, S. P. A., Remaley, A. T., Sviridov, D., & Chin-Dusting, J. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.168690 · Cited by 508 · cited 1×
“[5] showed in an experimental study that HDL and its major protein component—apolipoprotein A–I (apo A–I)—exhibit an antiinflammatory effect on human monocytes by inhibiting activation of CD11b.”
BackgroundSpeer, T., Rohrer, L., Blyszczuk, P., Shroff, R., Kuschnerus, K., Kränkel, N., Kania, G., Zewinger, S., Akhmedov, A., Shi, Y., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.02.009 · Cited by 310 · cited 1×
“[16] showed that symmetric dimethyl arginine (SDMA) could modify the HDL particle to mimic a damage-associated molecular pattern that activates toll-like receptor-2, linking abnormal HDL to innate immunity, endothelial dysfunction, and hypertension.”
BackgroundThe macrophage scavenger receptor at 30 years of age: current knowledge and future challenges
Greaves, D. R., & Gordon, S. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800066-jlr200 · Cited by 248 · cited 1×
“Recruited monocytes facing fatty deposits undergo activation and accumulate as foam cells [2, 3].”
BackgroundDysfunctional High-Density Lipoprotein in Patients on Chronic Hemodialysis
Yamamoto, S., Yancey, P. G., Ikizler, T. A., Jerome, W. G., Kaseda, R., Cox, B., Bian, A., Shintani, A., Fogo, A. B., Linton, M. F., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.013 · Cited by 199 · cited 2×
“[13] investigated the cellular cholesterol efflux and inflammatory response of macrophages exposed to HDL, in patients on hemodialysis treatment, compared to healthy controls.”
Background
Cited by
Monocyte‐to‐HDL‐cholesterol ratio as a prognostic marker in cardiovascular diseases
Ganjali, S., Gotto, A. M., Ruscica, M., Atkin, S. L., Butler, A. E., Banach, M., & Sahebkar, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27028 · Cited by 313
“94) compared with patients with low MHR (Kanbay et al., 2014).”
BackgroundMethodResultInfluentialCanpolat, U., Çetin, E. H., Cetin, S., Aydin, S., Akboga, M. K., Yayla, C., Turak, O., Aras, D., & Aydogdu, S. (2016) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029615594002 · Cited by 213
“In a recent study, Kanbay et al14 combined the circulating monocyte count and serum HDL-C in a proportion, as ‘‘MHR,’’ which was found as cross-sectionally associated with poor cardiovascular prognosis and arose as independent predictor of major cardiovascular events in patients with chronic kidney…”
BackgroundSelf-citationCetin, M. S., Ozcan Cetin, E. H., Kalender, E., Aydin, S., Topaloglu, S., Kisacik, H. L., & Temizhan, A. (2016) · Heart, Lung and Circulation · doi:10.1016/j.hlc.2016.02.023 · Cited by 194
Disorders of Lipid Metabolism in Chronic Kidney Disease
Bulbul, M. C., Dağel, T., Afşar, B., Ulusu, N. N., Kuwabara, M., Covic, A. C., & Kanbay, M. (2018) · Blood Purification · doi:10.1159/000488816 · Cited by 163
Self-citationCanpolat, U., Aytemir, K., Yorgun, H., Şahiner, L., Kaya, E. B., Çay, S., Topaloğlu, S., Aras, D., & Oto, A. (2015) · Europace · doi:10.1093/europace/euu291 · Cited by 130
“In a recent study,Kanbayet al.(9) combined the circulating monocyte count and serum HDL cholesterol in a fraction, as ‘M/H ratio’, which was found to be cross-sectionally associated with a poor cardiovascular prognosis and arose as an independent predictor of major cardiovascularevents inpatientswith chronic kidneydis…”
BackgroundKundi, H., Kızıltunç, E., Cetin, M., Cicekcioglu, H., Çetin, Z. G., Çiçek, G., & Örnek, E. (2016) · Herz · doi:10.1007/s00059-015-4393-1 · Cited by 108
Jiang, M., Yang, J., Zou, H., Li, M., Sun, W. Y., & Kong, X. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01638-6 · Cited by 117
“Kanbay and coworkers first reported that MHR could predict cardiovascular events in individuals with chronic kidney disease [13].”
BackgroundAkboğa, M. K., Balcı, K. G., Maden, O., Ertem, A. G., Kırbaş, Ö., Yayla, Ç., Açar, B., Aras, D., Kisacik, H. L., & Aydoğdu, S. (2016) · Biomarkers in Medicine · doi:10.2217/bmm-2015-0050 · Cited by 102
Monocyte/high-density lipoprotein ratio predicts the mortality in ischemic stroke patients
Bolayir, A., Gokce, S. F., Cigdem, B., Bolayir, H. A., Yildiz, O. K., Bolayir, E., & Topaktas, S. A. (2018) · Neurologia i Neurochirurgia Polska · doi:10.1016/j.pjnns.2017.08.011 · Cited by 98
“In this way, it is thought that HDL has antiinflammatory effects [8,9].”
BackgroundKarataş, M. B., Çanga, Y., Özcan, K. S., İpek, G., Güngör, B., Onuk, T., Durmuş, G., Öz, A., Karaca, M., & Bolca, O. (2015) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2015.10.049 · Cited by 97
“The first study indicated relation of increased value of MHR with adverse cardiovascular outcomes was conducted by Kanbay et al [9] in chronic kidney disease patients.”
BackgroundVillanueva, D. L. E., Tiongson, M. D. A., Ramos, J. D., & Llanes, E. J. B. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01242-6 · Cited by 104
“Previous studies have shown an association between high admission MHR with poorer cardiovascular outcomes among CKD patients [19], patients with atrial fibrillation [20], and ACS patients [22–25].”
Cetin, E. H. O., Cetin, M. S., Canpolat, U., Aydin, S., Topaloglu, S., Aras, D., & Aydogdu, S. (2015) · Biomarkers in Medicine · doi:10.2217/bmm.15.74 · Cited by 90
A New Inflammatory Marker: Elevated Monocyte to HDL Cholesterol Ratio Associated with Smoking
Yılmaz, M., & Kayançiçek, H. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7040076 · Cited by 84
Usta, A., Avcı, E., Bülbül, Ç. B., Kadı, H., & Adalı, E. (2018) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-018-0351-0 · Cited by 90
“The MHR has also been found to be correlated with hsCRP levels in diseases that are associated with chronic inflammation, such as cardiovascular disease [14], chronic kidney disease [12], abdominal aortic aneurysm [15], intracerebral hemorrhage [16], hypertension [17], and metabolic syndromes [18].”
BackgroundKundi, H., Gök, M., Kızıltunç, E., Çetın, M., Çiçekçioğlu, H., Çetin, Z. G., Karayiğit, O., & Örnek, E. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.08.036 · Cited by 82
Acikgoz, N., Kurtoğlu, E., Yagmur, J., Kapicioglu, Y., Cansel, M., & Ermis, N. (2018) · Angiology · doi:10.1177/0003319717704748 · Cited by 75
Chen, J. W., Li, C., Liu, Z. H., Shen, Y. H., Ding, F. H., Shu, X. Y., Zhang, R., Shen, W. F., Lu, L., & Wang, X. Q. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00191 · Cited by 76
“reported that MHR acts as an independent predictor for cardiovascular events in patients with chronic kidney disease and was increased in parallel with decreasing eGFR (12).”
BackgroundZhang, Y., Li, S., Guo, Y., Wu, N., Zhu, C., Gao, Y., Xu, R., Dong, Q., Liu, G., Sun, J., et al. (2016) · Annals of Medicine · doi:10.3109/07853890.2016.1168935 · Cited by 77
“patients with chronic kidney disease (9), the recurrence”
BackgroundAçıkgöz, S. K., Açıkgöz, E., Şensoy, B., Topal, S., & Aydoğdu, S. (2013) · Cardiology Journal · doi:10.5603/cj.a2016.0026 · Cited by 69
“[6] found that increased MHR is associated with major cardiovascular events in chronic kidney disease.”
BackgroundYou, S., Zhong, C., Zheng, D., Xu, J., Zhang, X., Liu, H., Zhang, Y., Shi, J., Huang, Z., Cao, Y., et al. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.11.022 · Cited by 70
A potential marker of bare metal stent restenosis: monocyte count - to- HDL cholesterol ratio
Uçar, F. M. (2016) · BMC Cardiovascular Disorders · doi:10.1186/s12872-016-0367-3 · Cited by 68
“Indeed, it has been demonstrated that higher MHR related to worse cardiovascular events in chronic kidney disease [28] or the isolated coronary ectasia patients [29].”
BackgroundUslu, A. U., Sekin, Y., Tarhan, G., Canakcı, N., Gündüz, M., & Karagülle, M. (2017) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029617741362 · Cited by 63
“Recently, monocyte to HDL-C ratio (MHR) has become a convenient marker in various cardiovascular disorders.(5,10) There are some advantages and disadvantages of MHR as a marker.”
BackgroundKarataş, A., Türkmen, E., Erdem, E., Düğeroğlu, H., & Kaya, Y. (2018) · Biomarkers in Medicine · doi:10.2217/bmm-2018-0048 · Cited by 60
Çiçek, G., Kundi, H., Bozbay, M., Yayla, Ç., & Uyarel, H. (2016) · Coronary Artery Disease · doi:10.1097/mca.0000000000000343 · Cited by 59
Balta, Ş., Celık, T., Öztürk, C., Kaya, M. G., Aparcı, M., Yıldırım, A. O., Demır, M., Kılıç, S., Aydın, İ., & Iyısoy, A. (2016) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2016.05.031 · Cited by 59
“So, the MHR, a routinely available, inexpensive and easily calculated index, may predict inflammation.(10) MHR has recently been investigated as a new predictor for major adverse cardiovascular outcomes.”
BackgroundKöseoğlu, H. İ., Pazarlı, A. C., Kanbay, A., & Demir, O. (2016) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029616677803 · Cited by 59
Wang, H., Shi, W., Yi, X., Zhou, Y., Wang, Z., & Sun, Y. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1076-6 · Cited by 61
Association of inflammatory factors and aging in Parkinson's disease
Jin, H., Gu, H., Mao, C., Chen, J., & Liu, C. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.135259 · Cited by 57
Aydin, E., Ateş, İ., Arikan, M. F., Yılmaz, N., & Dede, F. (2017) · Hypertension Research · doi:10.1038/hr.2017.36 · Cited by 54
Şirin, M. C., Korkmaz, S., Erturan, İ., Filiz, B., Arıdoğan, B. C., Çetin, E. S., & Yıldırım, M. (2020) · Anais Brasileiros de Dermatologia · doi:10.1016/j.abd.2020.02.008 · Cited by 58
Katipoğlu, Z., Mirza, E., Oltulu, R., & Katipoğlu, B. (2019) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2019.1611876 · Cited by 53
Inflammatory markers are beneficial in the early stages of cerebral venous thrombosis
Tekeşin, A., & Tunç, A. (2019) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20190001 · Cited by 49
Wu, T., Zheng, Y., Chen, Y., Yu, Z.-X., Ma, Y., & Xie, X. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1116-2 · Cited by 56
Guzmán, G., Marañón, C., & CYTED RIBLES Network (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.974826 · Cited by 50
“Given the pro-inflammatory activity of monocytes and the antiinflammatory effect of HDL, the monocyte/HDL ratio (MHR) has been proposed as a biomarker of systemic inflammation (141) and has been demonstrated to be a prognostic indicator of CV risk in patients with chronic kidney disease (120).”
BackgroundKarataş, M. B., Çanga, Y., İpek, G., Özcan, K. S., Güngör, B., Durmuş, G., Onuk, T., Öz, A., Şimşek, B., & Bolca, O. (2015) · Coronary Artery Disease · doi:10.1097/mca.0000000000000333 · Cited by 49
Yilmaz, S., Akboğa, M. K., Sen, F., Balcı, K. G., Aras, D., Temizhan, A., & Aydoğdu, S. (2016) · Biomarkers in Medicine · doi:10.2217/bmm-2016-0069 · Cited by 47
Arısoy, A., Altunkaş, F., Karaman, K., Karayakalı, M., Çelik, A., Ceyhan, K., & Zorlu, Ç. (2016) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029616663850 · Cited by 47
“predictor of cardiovascular events and is associated with a poor cardiovascular prognosis in patients with chronic kidney disease.(13) Kundi et al reported that MHR is significantly associated with CAD severity and found that the MHR was significantly higher in patients with stable CAD with high Synergy Between Percut…”
BackgroundResultThe effect of chronic kidney disease on lipid metabolism
Dinçer, N., Dağel, T., Afşar, B., Covic, A. C., Ortíz, A., & Kanbay, M. (2018) · International Urology and Nephrology · doi:10.1007/s11255-018-2047-y · Cited by 54
Self-citationNaicker, S. D., Cormican, S., Griffin, T. P., Maretto, S., Martin, W. P., Ferguson, J. P., Cotter, D., Connaughton, E. P., Dennedy, M. C., & Griffin, M. D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02845 · Cited by 51
Önalan, E. (2019) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.35.4.534 · Cited by 49
High-Density Lipoproteins: A Role in Inflammation in COPD
Kotlyarov, S. N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158128 · Cited by 46
Xu, L., Tian, L., Yan, Z., Wang, J., Xue, T., & Sun, Q. (2022) · Heart and Vessels · doi:10.1007/s00380-022-02172-2 · Cited by 44
“[27] found that MHR could independently predict major cardiovascular events during follow-up.”
BackgroundMonocyte-to-High-Density Lipoprotein Ratio Predicts the Outcome of Acute Ischemic Stroke
Liu, H., Liu, K., Pei, L., Gao, Y., Zhao, L., Sun, S., Wu, J. W., Li, Y., Fang, H., Song, B., et al. (2020) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.51151 · Cited by 47
Association of the Monocyte–to–High-Density Lipoprotein Cholesterol Ratio With Diabetic Retinopathy
Tang, X., Tan, Y. C. R. S., Yang, Y., Li, M., He, X., Lü, Y., Shi, G., Zhu, Y., Nie, Y., Li, H., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.707008 · Cited by 45
“Inflammation markers and monocytes play an important role in the development of diabetic complications (16, 26, 27).”
BackgroundDemirbaş, A., Elmas, Ö. F., Atasoy, M., Türsen, Ü., & Lotti, T. (2021) · Archives of Dermatological Research · doi:10.1007/s00403-020-02129-3 · Cited by 41
Karabay, E. A., Demіr, D., & Çerman, A. A. (2019) · Anais Brasileiros de Dermatologia · doi:10.1016/j.abd.2019.05.002 · Cited by 43
Hematological indices as indicators of inflammation induced by exposure to pesticides
Ruíz-Arias, M. A., Medina‐Díaz, I. M., Bernal-Hernández, Y. Y., Agraz‐Cibrián, J. M., González-Arias, C. A., Barrón-Vivanco, B. S., Herrera‐Moreno, J. F., Verdín-Betancourt, F. A., Zambrano‐Zaragoza, J. F., & Rojas‐García, A. E. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-23509-4 · Cited by 40
Kalyoncuoğlu, M., Biter, H. İ., Öztürk, S., Belen, E., & Can, M. M. (2020) · Coronary Artery Disease · doi:10.1097/mca.0000000000000848 · Cited by 40
Wei, X., Chen, F., Huang, J.-L., He, P., Wei, Y., Tan, N., Chen, J.-Y., Yu, D., & Liu, Y.-H. (2017) · Circulation Journal · doi:10.1253/circj.cj-17-0427 · Cited by 37
Ekizler, F. A., Çay, S., Açar, B., Tak, B. T., Kafes, H., Özeke, Ö., Çetin, E. H. Ö., Özcan, F., Topaloğlu, S., Tüfekçioğlu, O., et al. (2019) · Biomarkers in Medicine · doi:10.2217/bmm-2019-0089 · Cited by 35
An Association between Inflammation and Cerebral Venous Thrombosis: A Retrospective Study
Zhang, X., Ding, R., Li, H., Liu, Y., Ou, W., Hu, J., Tian, Y., & Wang, Q. (2021) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2021.106084 · Cited by 37
Xi, J., Men, S., Nan, J., Yang, Q., & Dong, J. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01741-8 · Cited by 35
“The MHR is an indicator of atherosclerosis that evaluates inflammation and dyslipidemia [21].”
Sağ, S., Yıldız, A., Kaderlï, A. A., Gul, C. B., Bedir, Ö., Çeğilli, E., Özdemir, B. H., Can, F. E., & Aydınlar, A. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2016-0005 · Cited by 35
“However, the literature on MHR is limited and there is only one study about the clinical use of MHR in patients with renal failure [41].”
BackgroundAghaei, M., Bahreiny, S. S., Zayeri, Z. D., Davari, N., Abolhasani, M. M., & Saki, N. (2025) · Health Science Reports · doi:10.1002/hsr2.70488 · Cited by 35
“Therefore, increasing MHR can be used as a new marker of cardiovascular prognosis or inflammation in T2DM patients and its complications [51, 123].”
Monocyte to HDL and Neutrophil to HDL Ratios as Potential Ischemic Stroke Prognostic Biomarkers
Gkantzios, A., Tsiptsios, D., Karapepera, V., Karatzetzou, S., Kiamelidis, S., Vlotinou, P., Γιαννακού, Ε., Karampina, E., Paschalidou, K., Kourkoutsakis, N., et al. (2023) · Neurology International · doi:10.3390/neurolint15010019 · Cited by 36
“An important phase in the development of atherosclerotic plaques is the migration of monocytes into the intima, where they differentiate into macrophages, which through the use of their scavenger receptors absorb oxidized low-density lipoprotein (ox-LDL) [36,37].”
BackgroundInfluentialŞaşkın, H., Özcan, K. S., & Yılmaz, S. (2016) · Interactive Cardiovascular and Thoracic Surgery · doi:10.1093/icvts/ivw376 · Cited by 34
“[25] observed that the M/HDL-C ratio was associated with poor outcome in patients with chronic kidney disease.”
BackgroundLi, J., Yao, R.-Q., Liu, S., Zhang, Y., Yao, Y.-M., & Tian, Y. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.741015 · Cited by 33
Çağdaş, M., Karakoyun, S., Yesın, M., Rencüzoğulları, İ., Karabağ, Y., Uluganyan, M., Ozan Gürsoy, M., Artaç, İ., İliş, D., Atalay, E., et al. (2018) · Europe PMC (PubMed Central) · doi:10.6515/acs.201801_34(1).20170823a · Cited by 33
Monocyte to HDL ratio: a novel marker of resistant hypertension in CKD patients
Gembillo, G., Siligato, R., Cernaro, V., Satta, E., Conti, G., Salvo, A., Romeo, A., Calabrese, V., Sposito, G., Ferlazzo, G., et al. (2021) · International Urology and Nephrology · doi:10.1007/s11255-021-02904-9 · Cited by 32
Assessment of Monocyte/HDL Ratio in Branch Retinal Vein Occlusion
Şatırtav, G., Mirza, E., Oltulu, R., Mirza, G. D., & Kerimoğlu, H. (2019) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2019.1569244 · Cited by 34
Sahpolat, M., Ayar, D., Ari, M., & Karaman, M. A. (2021) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2021.19.1.112 · Cited by 31
“chronic renal failure patients, and to be related with a poor prognosis for cardiovascular mortality [21].”
BackgroundSelf-citationIncreased monocyte-to-HDL cholesterol ratio is related to cardiac syndrome X
Doğan, A., & Oylumlu, M. (2017) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2017.1299521 · Cited by 31
“[33] conducted an average 33-month follow-up study with 340 patients with stage-1–5 chronic kidney failure and found that increased MHR was associated with poor cardiovascular profile and was a predictor of major cardiovascular events.”
BackgroundVural, G., & Gümüşyayla, Ş. (2018) · Medicine · doi:10.1097/md.0000000000012857 · Cited by 31
“As a new vascular inflammatory marker, MHR was investigated in a series of clinical studies: Kanbay et al demonstrated that an increase in MHR was associated with a decreased glomerular filtration rate in chronic kidney disease;([10]) Canpolat et al found that high MHR was associated with the slow coronary phenomenon.”
BackgroundMonocyte/HDL ratio and lymphocyte/monocyte ratio in patients with pseudoexfoliation syndrome.
Mirza, E., Oltulu, R., Katipoğlu, Z., Mirza, G. D., & Özkağnıcı, A. (2020) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2018.1545913 · Cited by 29
Korkmaz, A., Demir, M., Unal, S., Yildiz, A., Ozyazgan, B., Demirtas, B., Elalmis, O. U., Ileri, M., & Guray, U. (2017) · International Journal of the Cardiovascular Academy · doi:10.1016/j.ijcac.2017.05.008 · Cited by 29
Serçelik, A., & Besnili, A. F. (2018) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2017.06.021 · Cited by 29
“Besides its anti-inflammatory properties, HDL-C is also an important marker for the prognosis of cardiovascular disease.19 Kanbay et al.20 reported that MHR increased with decreasing estimated glomerular filtration rate in predialytic chronic kidney disease patients and that a higher MHR was associated with a worse ca…”
BackgroundChen, S.-A., Zhang, M.-M., Zheng, M., Liu, F., Sun, L., Bao, Z.-Y., Chen, F., Li, H., & Gu, X. Q. (2020) · BMC Cardiovascular Disorders · doi:10.1186/s12872-020-01670-3 · Cited by 30
Kutlu, Ö. (2019) · Cutaneous and Ocular Toxicology · doi:10.1080/15569527.2019.1701485 · Cited by 31
Oylumlu, M., Oylumlu, M., Arık, B., Demir, M., Özbek, M., Arslan, B., Acun, B., Polat, N., Akıl, M. A., & Bilik, M. Z. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13973 · Cited by 27
Lin, J., Li, Z., Xu, J., Pan, M., Yin, T., Wang, J., Sun, Q., Zheng, W., & Chen, R. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02149-2 · Cited by 28
“A small-scale cohort study from Turkey found that CKD patients with MHR levels in the highest tertile had a higher risk of concurrent cardiovascular events [27].”
BackgroundYayla, K. G., Canpolat, U., Yayla, Ç., Akboğa, M. K., Akyel, A., Akdi, A., Çiçek, G., Özcan, F., Turak, O., & Aydoğdu, S. (2017) · PubMed · doi:10.6515/acs20160427a · Cited by 27
Self-citationWu, D., Lan, Y., Xu, Y., Xu, S., Huang, Y., Balmer, L. A., Mahara, G., Xu, W., Wang, W., & Wu, S. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01701-7 · Cited by 27
“, the monocyte-to-HDL-C ratio (MHR), has been proposed to indicate low-grade metabolic inflammation [16].”
BackgroundEkizler, F. A., & Çay, S. (2019) · BMC Cardiovascular Disorders · doi:10.1186/s12872-019-1100-9 · Cited by 26
Omar, T., Karakayalı, M., Yesın, M., Alaydın, H. C., Karabağ, Y., & Gümüşdağ, A. (2021) · Biomarkers in Medicine · doi:10.2217/bmm-2020-0705 · Cited by 27
Tok, D., Turak, O., Yayla, Ç., Özcan, F., Tok, D., & Cagli, K. E. (2016) · Biomarkers in Medicine · doi:10.2217/bmm-2016-0071 · Cited by 25
Self-citationZhou, Y., Wang, L., Jia, L., Lu, B., Gu, G., Bai, L., & Cui, W. (2020) · Lipids · doi:10.1002/lipd.12276 · Cited by 24
Türkmen, D., Altunışık, N., & Şener, S. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13639 · Cited by 24
Kadihasanoglu, M., Karabay, E., Yucetas, U., Erkan, E., & Ozbek, E. (2018) · Aktuelle Urologie · doi:10.1055/s-0042-123163 · Cited by 23
“MHR is a newly introduced inflammatory marker that combined the predictive value of traditional risk factors such as the circulating monocyte count and HDL-C into a single ratio [20].”
BackgroundYalınbaş, D., Eroglu, S., Sarıakçalı, B., Bozali, E., Özeç, A. V., & Erdoğan, H. (2021) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2020.1849739 · Cited by 28
“Recent studies highlighted that MHR was a novel inflammation and oxidative stress biomarker in patients with cardiovascular diseases and chronic kidney disease.(22,23) Furthermore, MHR has been found to be significantly higher in ocular diseases such as retinal vein occlusion, central serous retinopathy, and pseudoexf…”
BackgroundCagli, K. E., Tok, D., Turak, O., Günertem, E., Yayla, Ç., Lafçı, G., Ulaş, M. M., & Çağlı, K. (2016) · Biomarkers in Medicine · doi:10.2217/bmm-2016-0157 · Cited by 25
Self-citationOh, E. S., You, Z., Nowak, K. L., & Jovanovich, A. J. (2022) · Kidney360 · doi:10.34067/kid.0007922021 · Cited by 24
“7 Current smoking, n (%) 456 (13) 118 (12) 163 (13) 175 (15) 195 (18) 127 (12) 134 (11) CVD, n (%) 1152 (34) 278 (28) 414 (33) 460 (41) 317 (29) 364 (34) 471 (39) Diabetes, n (%) 1573 (46) 410 (41) 592 (47) 571 (50) 485 (44) 491 (46) 597 (49) # Antihypertensives, mean6SD 2.”
BackgroundA New Predictor for Obstructive Sleep Apnea Syndrome: Monocyte to HDL Ratio
Atan, D., Kundi, F. C. S., Özcan, K. M., & Dere, H. (2016) · Indian Journal of Otolaryngology and Head & Neck Surgery · doi:10.1007/s12070-016-0980-6 · Cited by 22
Canpolat, A. G., Emral, R., Keskin, Ç., Canlar, Ş., Şahin, M., & Çorapçıoğlu, D. (2019) · Biomarkers in Medicine · doi:10.2217/bmm-2018-0451 · Cited by 22
Sucato, V., Corrado, E., Manno, G., Amata, F., Testa, G., Novo, G., & Galassi, A. R. (2022) · Angiology · doi:10.1177/00033197211034267 · Cited by 21
“The MHR is considered a predictor of major cardiovascular events.(60,61) Monocytes represent the majority of the inflammatory cells infiltrating the arterial wall in early atherogenesis and are involved in the release of pro-inflammatory and pro-oxidative cytokines at sites of inflammation; thus, they play an importan…”
BackgroundZhan, X., Pan, D., Wei, X., Wen, D., Yan, C., & Xiao, J. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.03.011 · Cited by 22
Assessing systemic inflammatory markers in psoriasis: A retrospective study
Solak, B., & Kara, R. Ö. (2024) · Tropical Medicine & International Health · doi:10.1111/tmi.14052 · Cited by 20
“The Monocyte-to-HDL cholesterol Ratio (MHR) is linked to systemic inflammation, serving as a predictive marker for cardiovascular disease risk [16, 17].”
Chen, B.-W., Liu, J.-J., Xing, J., Liu, H., Wei, Y., Xue, X.-F., Gu, H., & Tao, H. (2022) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296221079334 · Cited by 20
“Kanbay et al.(9) found that an increase in MHR in patients with chronic renal insufficiency is related to the occurrence of cardiac adverse events, and Canpolat et al.”
BackgroundXu, L., Li, D., Song, Z., Liu, J., Zhou, Y., Yang, J., & Wen, P. (2024) · Renal Failure · doi:10.1080/0886022x.2024.2331614 · Cited by 20
“…related to several comorbidities and the outcome in patients with CKD. Kanbay et al. showed that higher MHR values were related to both composite cardiovascular events [hazard ratio (HR)=4.91, 95%CI, 2.88-6.94] and higher mortality rate (HR = 2.24, 95%CI, 1.85-2.39) in patients with CKD [43].”
BackgroundInfluentialChen, M., Shi, W., Shi, C., Zhou, Y., & Sun, Y. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01226-6 · Cited by 20
“MHR was determined as blood monocyte count ratio to high-density lipoprotein cholesterol concentration [29].”
MethodGüler, B., Doğan, E., & Onbaşı, K. (2020) · Meandros Medical And Dental Journal · doi:10.4274/meandros.galenos.2020.41033 · Cited by 19
Wang, Q., Meng, Y., Cao, W., Du, W., Liu, Y., Yan, Y., Luo, L., & Ma, X. (2018) · Biomarkers in Medicine · doi:10.2217/bmm-2016-0362 · Cited by 20
Selçuk, M., Yıldırım, E., & Şaylık, F. (2019) · Biomarkers in Medicine · doi:10.2217/bmm-2019-0062 · Cited by 19
Sun, Y., Lü, J., Zheng, D., Qian, J., Zhang, H., Xing, D. M., Rong, F., Cao, Y., Liu, C., & You, S. (2020) · Acta Neurologica Belgica · doi:10.1007/s13760-020-01418-y · Cited by 19
Özlü, E., Karadağ, A. S., Toprak, A. E., Uzunçakmak, T. K., Gerin, F., Aksu, F., Özakpınar, Ö. B., & Akdeniz, N. (2016) · Dermatology · doi:10.1159/000447587 · Cited by 19
Li, Y., Li, S., Ma, Y., Li, J., Lin, M., & Wan, J. (2020) · Coronary Artery Disease · doi:10.1097/mca.0000000000000881 · Cited by 21
Li, C., Fan, H., Liu, Y., Zeng, L., Chen, P., Duan, C., Liang, H., & He, P. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-4876 · Cited by 18
“A previous study conducted in patients revealed that the MHR can be regarded as an independent predictor of major cardiovascular events (16).”
Wang, L., Zhang, Y., Yu, B., Zhao, J., Zhang, W., Fan, H., Ren, Z., & Liang, B. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1127425 · Cited by 18
“In 2004, for the first time, increased MHR was found to be strongly associated with an elevated risk of cardiovascular events in patients with chronic kidney disease (44).”
BackgroundBaek, K., & Chung, I. (2017) · Journal of Korean Medical Science · doi:10.3346/jkms.2017.32.9.1415 · Cited by 17
“MHR is a novel inflammatory marker identified by Kanbay et al. (14) as an independent predictor of cardiovascular disease prediction in patients with chronic kidney disease.”
BackgroundZhang, M., Wu, S., Xu, S., & Chen, S. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.1957265 · Cited by 17
“ratio (MHR)’ has been posited for rapid assessment of the atherosclerotic severity through evaluating dyslipidemia and inflammation [20].”
BackgroundBilgin, M., Akkaya, E., & Dokuyucu, R. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13195940 · Cited by 16
“Kanbay et al. stated that MHR was an independent prognostic factor of major cardiovascular events in the follow-up of chronic kidney disease patients [20].”
BackgroundMethod
Metadata
- Authors
- Kanbay, M., Solak, Y., Unal, H. U., Kurt, Y. G., Gok, M., Cetinkaya, H., Karaman, M., Oguz, Y., Eyileten, T., Vural, A., Covic, A., Goldsmith, D., Turak, O., & Yilmaz, M. I.
- Affiliations
- Istanbul Medeniyet University (TR)
- Gülhane Askerî Tıp Akademisi (TR)
- Spitalul Clinic Dr. C. I. Parhon (RO)
- St Thomas' Hospital (GB)
- Türkiye Yüksek İhtisas Hastanesi (TR)
- Corresponding author
- Kanbay, Mehmet
- Venue
- International Urology and Nephrology
- Published
- 2014-05-23
- Volume
- 46
- Issue
- 8
- Pages
- 1619-1625
- ISSN
- 0301-1623 (ISSN-L)
- 1573-2584
- OpenAlex
- W2035731392
- Cited by
- 276
- References
- 17
- Citations by year
- 2026: 9 · 2025: 24 · 2024: 32 · 2023: 34 · 2022: 30 · 2021: 34 · 2020: 31 · 2019: 27 · 2018: 18 · 2017: 13 · 2016: 17 · 2015: 6
- FWCI
- 9.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- International Urology and Nephrology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- monocyte count, HDL cholesterol, chronic kidney disease, cardiovascular events, all-cause mortality, estimated glomerular filtration rate, cardiovascular risk prediction
- MeSH terms
- Adult, Aged, Cardiovascular Diseases, Cross-Sectional Studies, Female, Glomerular Filtration Rate, Humans, Kidney Failure, Chronic, Leukocyte Count, Cholesterol, HDL, Male, Middle Aged, Monocytes, Myocardial Infarction, Prospective Studies, Stroke, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.